CMR Versius / Versius Plus

The second robotic surgery platform that actually scaled

CMR Surgical’s headline number from the SAGES 2026 meeting in Tampa is clean: 45,000 patients treated globally with Versius. That is a decade of multi-specialty clinical data across more than thirty countries, and it puts a Cambridge, UK company in the seat that has been functionally vacant in surgical robotics since da Vinci shipped — the credible number-two platform. The market did not have one for a long time. It does now.

The same announcement marked CMR’s formal U.S. debut. Versius Plus, the next-generation system, received FDA 510(k) clearance in December 2025 for cholecystectomy, and in April 2026 CMR filed a follow-on 510(k) to extend U.S. indications into gynecology. American hospitals shopping for soft-tissue surgical robotics had one option for the last decade. They now have two.

What Versius is, and what makes it different from da Vinci

Da Vinci hangs every robotic arm off a single boom over the table. Installing one is an OR retrofit; once installed, the machine is the gravitational center of the room and everything around it works around the machine. Versius puts each arm on its own independent cart. A given case uses two, three, or four arms; the rest sit in the hallway. The same platform can be wheeled from a gynecology OR to a thoracic OR the next morning. No structural changes, no dedicated room.

Optically, Versius Plus runs 3D HD with vLimeLite fluorescence imaging — ICG dye for real-time perfusion, biliary anatomy, and tissue viability during the procedure. The surgeon console is open rather than enclosed, which lets the surgeon sit or stand and rotate posture on long cases. For thoracic or extended colorectal work where surgeon fatigue compounds into outcome variability, posture flexibility is not a luxury.

CMR describes the underlying strategy as “software beats metal” — design the hardware light and modular, push complexity into the software and the consumables stack, and let marginal deployment cost fall over time. That is the inverse of da Vinci’s product philosophy, and it is the bet that distinguishes the two platforms in 2026.

Why we care for LostJobs

Versius does not take a surgeon’s job. The same was true of da Vinci Xi. What surgical robotics does instead is compress procedure time and lift output per surgeon, which lets hospital systems handle rising case volume without growing surgeon headcount on the prior trajectory. Slower hiring, not layoffs.

Versius adds a second effect that da Vinci alone could not: it ends single-vendor dominance. American hospitals comparing two platforms gain real leverage on capital cost, instrument consumables, training contracts, and service. Over years that pressure compresses total cost of ownership — and at the margin, that flows downstream into compensation growth for the surgeons, scrub nurses, anesthetists, and techs whose work the platform organizes. The job titles persist. The slope of their pay curves does not.

If surgical robotics is on your professional horizon — as a surgeon evaluating training, as a hospital administrator running capital plans, as a tech mapping the OR’s adjacent roles — Versius is now the platform you compare da Vinci against, not the underdog you mention in a footnote.